These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 3045435

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
    Hutton JT, Morris JL, Román GC, Imke SC, Elias JW.
    Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
    [Abstract] [Full Text] [Related]

  • 4. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
    Feldman RG, Mosbach PA, Kelly MR, Thomas CA, Saint Hilaire MH.
    Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
    [Abstract] [Full Text] [Related]

  • 5. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA, Nelson MV, Berchou RC, Galloway MP, Kesaree N, Kareti D, Schlick P.
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [Abstract] [Full Text] [Related]

  • 6. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
    Sage JI, Mark MH.
    Clin Neuropharmacol; 1988 Apr; 11(2):174-9. PubMed ID: 3378226
    [No Abstract] [Full Text] [Related]

  • 7. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM, Breck L, Kutt H, McDowell FH.
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
    Bush DF, Liss CL, Morton A.
    Neurology; 1989 Nov; 39(11 Suppl 2):101-4; discussion 105. PubMed ID: 2685646
    [Abstract] [Full Text] [Related]

  • 10. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK, Rinne JO.
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH, Sage JI.
    Ann Clin Lab Sci; 1989 Nov; 19(2):101-6. PubMed ID: 2665626
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
    Goetz CG, Tanner CM, Shannon KM, Carroll VS, Klawans HL, Carvey PM, Gilley D.
    Neurology; 1988 Jul; 38(7):1143-6. PubMed ID: 3290706
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG, Tanner CM, Gilley DW, Klawans HL.
    Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.